Related references
Note: Only part of the references are listed.European cancer mortality predictions for the year 2013
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2013)
Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Deniz A. Ucar et al.
Anti-Cancer Agents in Medicinal Chemistry (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
Amir Avan et al.
CANCER RESEARCH (2013)
Current concepts and novel targets in advanced pancreatic cancer
Patrick Michl et al.
GUT (2013)
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
C. Hage et al.
CELL DEATH & DISEASE (2013)
Postoperative Prognostic Predictors of Pancreatic Ductal Adenocarcinoma: Clinical Analysis and Immunoprofile on Tissue Microarrays
Joo Kyung Park et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemoresistance of invasive micropapillary carcinoma of the breast
Sophie Doublier et al.
BMC CANCER (2012)
Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer
Kristen S. Hill et al.
PLOS ONE (2012)
Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?
Jie-Er Ying et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
STAT5b as Molecular Target in Pancreatic Cancer-Inhibition of Tumor Growth, Angiogenesis, and Metastases
Christian Moser et al.
NEOPLASIA (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma
Guang-Hui Zhu et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
Chenwei Li et al.
GASTROENTEROLOGY (2011)
Stromal biology and therapy in pancreatic cancer
Albrecht Neesse et al.
GUT (2011)
Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger et al.
MOLECULAR CANCER THERAPEUTICS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Advanced pancreatic carcinoma: current treatment and future challenges
Anastasios Stathis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Modeling Pancreatic Cancer In Vivo From Xenograft and Carcinogen-Induced Systems to Genetically Engineered Mice
Yongzeng Ding et al.
PANCREAS (2010)
Targeting Heat-Shock Protein 90 Improves Efficacy of Rapamycin in a Model of Hepatocellular Carcinoma in Mice
Sven A. Lang et al.
HEPATOLOGY (2009)
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
Hongkui Jin et al.
CANCER RESEARCH (2008)
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Sven A. Lang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Development and characterization of gemcitabine-resistant pancreatic tumor cells
Ami N. Shah et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth
Sven A. Lang et al.
CLINICAL CANCER RESEARCH (2007)
The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling
Takao Ide et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
c-Met is essential for wound healing in the skin
Jolanta Chmielowiec et al.
JOURNAL OF CELL BIOLOGY (2007)
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells
Todd W. Bauer et al.
MOLECULAR CANCER THERAPEUTICS (2006)
p8 is a new target of gemcitabine in pancreatic cancer cells
V Giroux et al.
CLINICAL CANCER RESEARCH (2006)
Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase
J Zhou et al.
CANCER RESEARCH (2006)
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair
CG Huh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
M Bentires-Alj et al.
ONCOGENE (2003)
Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer
Z Lu et al.
PANCREAS (2000)
Share Paper
